CN101805406A - Monoclonal antibody of human insulin-like growth factor binding protein-1, relative host cell, diagnostic reagent and diagnostic reagent kit - Google Patents
Monoclonal antibody of human insulin-like growth factor binding protein-1, relative host cell, diagnostic reagent and diagnostic reagent kit Download PDFInfo
- Publication number
- CN101805406A CN101805406A CN200910224645A CN200910224645A CN101805406A CN 101805406 A CN101805406 A CN 101805406A CN 200910224645 A CN200910224645 A CN 200910224645A CN 200910224645 A CN200910224645 A CN 200910224645A CN 101805406 A CN101805406 A CN 101805406A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- growth factor
- binding protein
- human insulin
- factor binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a monoclonal antibody of human insulin-like growth factor binding protein-1, a monoclonal antibody host cell, a diagnostic reagent with the monoclonal antibody of the human insulin-like growth factor binding protein-1and a diagnostic reagent kit, wherein antigen of the monoclonal antibody is antigenic determinant of the human insulin-like growth factor binding protein-1; preferably, the antigenic determinant comprises an amino acid sequence represented by SEQIDNO:1; and the monoclonal antibody host cell contains the monoclonal antibody of the human insulin-like growth factor binding protein-1. The monoclonal antibody of the human insulin-like growth factor binding protein-1 can perform specific detection on the human insulin-like growth factor binding protein-1, and the prepared diagnostic reagent has high specificity of premature rupture of membrane diagnosis, rapid reaction, low cost and suitability for large-scale popularization and application.
Description
Technical field
The present invention relates to genetically engineered and immunological technique field, more specifically, relate to the monoclonal antibody technique field, be meant the monoclonal antibody of a kind of human insulin-like growth factor binding protein white-1, relevant host cell, diagnostic reagent and diagnostic kit especially.
Background technology
Fetal membrane breaks before term birth, be called premature rupture of fetal membrane (Premature rupture of membrane, PROM); The incidence of premature rupture of fetal membrane is about 10%, wherein clinically about 30% pregnant woman is carried out PROM and checks; Present national pregnant woman's quantity is 1000～1400 about ten thousand.
Therefore, premature rupture of fetal membrane is one of common cause of premature labor and newborn infant's complication, also is one of the most thorny treatment difficult point of running into of current clinical obstetrics.Diagnosis can increase fetus morbidity and mortality ratio after rupture of membranes takes place 24 hours.PROM is in case generation can jeopardize female youngster's life if deal with improperly.Because the diagnostic method difference, and make diagnosis that bigger difference be arranged, on handling, give the false positive case unnecessary intervention, can cause premature labor, otherwise, allow false negative person's wait blindly, can cause severe infections.Especially vast Rural areas, harm more very.
To premature rupture of fetal membrane carry out in time, diagnosis accurately is prevention pregnant and lying-in women and infection of newborn, dead key.
The current main clinically both at home and abroad methods analyst that adopts is as follows:
1) hydrocolpos (flowing water): there is visible hydrops (amniotic fluid pond) in vagina, and obvious seepage flow is perhaps arranged from the uterine neck to the posterior fornix of vagina, supports the diagnosis of rupture of membranes strongly.Yet, be not that each patient has obvious hydrops.In addition, rupture of membranes, particularly premature rupture of fetal membrane may continue several hours and can see that just obvious sepage is arranged.As seen IAI caused the possibility of newborn infant's complication even fetal asphyxia significantly to increase before sepage occurred.
2) amniotic fluid crystal method: amniotic fluid air-dry back on slide presents fernlike crystal at microscopically.Owing on slide, polluted by fingerprint, seminal fluid and cervical mucus easily, false positive may occur.Dry swab or sample may be caused false negative (5-10%) by blood contamination.
3) nitrazine test paper: the pH test paper becomes blue in amniotic fluid.Susceptibility and specificity are respectively 90.7% and 77.2%.When occurring alkaline urine, blood, seminal fluid, vaginal bacteria inflammation or trichomonad inflammation etc. in the vagina, false positive can occur, false positive rate is 1%-17%.
Any appearance in above three kinds of situations when all satisfying, three kinds of conditions can be diagnosed as rupture of membranes, if can be suspected to be rupture of membranes.
But clinical experience proves that the diagnosis rupture of membranes is not to satisfy all three kinds of conditions, and when both existed among the three, can think had clinical correlation.Dissatisfied when Case definition, when the false positive of generation rupture of membranes and false negative, the diagnostic result that draws is ambiguous often.When diagnosis can not be drawn a conclusion, may need to adopt amnioscopy or amniocentesis injection dyestuff (azovan blue or fluorescein), positive to determine whether.
4) amnioscopy: can be to suspicious case history, but need certain device, technology, and can not detect in some cases at direct viewing condition of fetal membrane under the amnioscope, as placenta when preposition.
5) amniotic fluid dyeing injection: be present unique detection method that can reach 100% accuracy, its process relates in the indigo injection amniotic cavity of dilution, determines by having or not color to ooze out (cotton balls dyeing) in the observation vagina whether fetal membrane breaks in 20-30 minute.Amniotic fluid dyeing injection is to detect ROM method the most accurately on the one hand, but is simultaneously wound (needing amniocentesis) to be arranged and expensive method.Amniocentesis has certain risk to the pregnant woman, comprises bell, infection, iatrogenic rupture of membranes, reaches miscarriage (about 1/270).
Need badly clinically at present a kind of easy and simple to handle, quick, instrument is relied on the PROM diagnostic method little, that Costco Wholesale is lower, significantly reduce the danger of pregnant and lying-in women and neonatal mortality and infection rate, improve the prenatal and postnatal care quality.
Limitation at traditional method, adopt some immunodetection indexs clinically in succession, as vaginal washing fluid human chorionic gonadotrophin (human chorionic gonadotropin, hCG), AFAFP (alpha-fetoprotein, AFP), cervical secretions fetal type fibronectin (fetal fibronectin, fFN), the cervical secretions insulin-like growth factor binding protein (insulin-like growth factor binding protein-1, IGFBP-1) and placenta α 1-microballoon white (PAMG-1) etc. be used for the laboratory diagnosis of PROM.Concrete grammar and principle are as follows:
1) vaginal washing fluid hCG measures: hCG is a kind of glycoprotein hormones, and hCG content is very high in the amniotic fluid, and hCG content is very low in the normal pregnancy uterine neck vaginal secretion.False positive and false negative are all less than 10%.If but be mixed with blood in the vaginal washing fluid, then false positive rate will obviously raise, and accuracy rate of diagnosis descends, and this is the shortcoming of this law maximum.
2) amniotic fluid AFP measures: AFP content reaches the peak in the whole pregnancy duration amniotic fluid when pregnant 13～14 weeks, reduces subsequently, and continues to childbirth always; AFP content is close in pregnant late period female blood and the amniotic fluid, so this law is more responsive to the diagnosis before pregnant 36 weeks.
3) cervical secretions FFN measures: high 10 times in female blood of the FFN concentration ratio in the amniotic fluid and the urine.During rupture of membranes, FFN can flow into vagina with amniotic fluid.Use double antibodies sandwich spot immune method FFN in official's neck secretory product of normal pregnancies and premature rupture of fetal membrane pregnant woman is detected discovery, the former positive rate is 6.0%, and the latter is 95.0%, and FFN has higher susceptibility to diagnosis PROM.
4) cervical secretions placenta α 1 microglobulin (PAMG-1) is measured: just appear in the vaginal secretions behind the PAMG-1 rupture of membranes, in amniotic fluid dense (2000～25000ng/ml), concentration in the blood is low by (5～25ng/ml), and when fetal membrane was intact, the background concentration in the uterine neck vaginal secretions was extremely low by (about 0.05～0.22ng/ml).This method is convenient and swift, and accuracy is higher than 99%, and false positive and false negative are all less than 1%.
5) cervical secretions IGFBP-1 measures: IGFBP-1 is mainly by decidual cell, female youngster's liver, the synthetic justacrine of gonad granulocyte, judge with the content of IGFBP-1 in the immunochromatographyassay assay cervical secretions and to have or not premature rupture of fetal membrane, positive predictive value is 97.0%, and negative predictive value is 93.2%.
Immune diagnostic method is diagnosed PROM accuracy height, and is easy and simple to handle, is expected to become the gold standard of diagnosing premature rupture of fetal membrane.But China has not yet to see the product of registration listing.Therefore, be badly in need of the new PROM diagnostic kit of exploitation.
Summary of the invention
Main purpose of the present invention is exactly the problems and shortcomings at above existence, the monoclonal antibody of a kind of human insulin-like growth factor binding protein white-1, relevant host cell, diagnostic reagent and diagnostic kit are provided, the monoclonal anti physical efficiency specific detection human insulin-like growth factor binding protein white-1 of this human insulin-like growth factor binding protein white-1, Zhi Bei diagnostic reagent diagnosing premature rupture of fetal membrane specificity height thus, be quick on the draw, cost is low, be suitable for large-scale promotion application.
In order to solve above-mentioned purpose, in a first aspect of the present invention, the monoclonal antibody of a kind of human insulin-like growth factor binding protein white-1 is provided, has been characterized in, the antigen of described monoclonal antibody is the antigenic determinant of human insulin-like growth factor binding protein white-1.
Preferably, described antigenic determinant comprises the aminoacid sequence shown in the SEQ ID NO:1.
More preferably, described antigenic determinant is the aminoacid sequence shown in the SEQ ID NO:1.
In a second aspect of the present invention, a kind of monoclonal antibody host cell is provided, be characterized in, contain the monoclonal antibody of above-mentioned human insulin-like growth factor binding protein white-1.
Preferably, described monoclonal antibody host cell is a mouse hybridoma cell.
In a third aspect of the present invention, a kind of diagnostic reagent is provided, be characterized in, contain the monoclonal antibody of above-mentioned human insulin-like growth factor binding protein white-1.
Preferably, the content of the monoclonal antibody of described human insulin-like growth factor binding protein white-1 is 4ug/ml.
In a fourth aspect of the present invention, a kind of diagnostic kit is provided, be characterized in that described diagnostic kit is a colloidal gold strip, the monoclonal antibody of above-mentioned human insulin-like growth factor binding protein white-1 is as colloid gold label antibody/capture antibody.
Preferably, every described colloidal gold strip comprises the described human insulin-like growth factor binding protein of 0.1-50ug-1 monoclonal antibody in vain.
In a fifth aspect of the present invention, a kind of diagnostic kit is provided, be characterized in that described diagnostic kit is the ELISA test kit, according to the monoclonal antibody of the arbitrary described human insulin-like growth factor binding protein of claim 1-3 white-1 as enzyme labelled antibody/coated antibody.
Beneficial effect of the present invention is: the antigen of the monoclonal antibody of human insulin-like growth factor binding protein of the present invention white-1 is the antigenic determinant of human insulin-like growth factor binding protein white-1, preferably include the aminoacid sequence shown in the SEQ ID NO:1, energy specificity high detection human insulin-like growth factor binding protein white-1, be quick on the draw, cost is low, is suitable for large-scale promotion application.
Embodiment
The inventor obtains the monoclonal antibody of a kind of human insulin-like growth factor binding protein white-1 through extensive and deep research, and this monoclonal antibody has excellent specificity keying action to human insulin-like growth factor binding protein white-1.Finished the present invention on this basis.
In order more to be expressly understood technology contents of the present invention, describe in detail especially exemplified by following examples.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, people such as Sambrook for example, molecular cloning: laboratory manual (NewYork:Cold Spring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1 antigen prepd (aminoacid sequence shown in the SEQ ID NO:1)
The synthetic post of peptide is placed Pioneer
TMIn the peptide synthesizer, and under nitrogen, carry out the synthetic of peptide according to the aminoacid sequence of little peptide order.
With the THF washing resin about 5 minutes.
Filtration is also centrifugal in cold diethyl ether with filtrate, pour out supernatant and repeat that cold diethyl ether is centrifugal to be precipitated fully until peptide, and with gained peptide crude product at preparation property C18 purification by silica gel column chromatography, use the acetonitrile gradient wash-out, collection contains the wash-out flow point and the lyophilize of target peptide, obtains target peptide.
Embodiment 2 animal immunes
With antigen and the KLH coupling that embodiment 1 obtains, get conjugate 4mg and be dissolved in the 5ml physiological saline, mix with complete Freund's adjuvant 1: 1 (volume ratio), get 8 all ages magnetic Balb/c mouse, carry out animal immune according to following testing program:
(1) initial immunity (little peptide 50 μ g add the subcutaneous multi-point injection of Freund's complete adjuvant, 1ml 0.2ml/ point);
(dosage is the same, adds the freund 's incomplete adjuvant subcutaneous injection, 0.5ml) in (2) three week back immunity for the second time
Immunity for the third time after (3) three weeks (dosage is the same, does not add the adjuvant subcutaneous injection, and blood sampling is surveyed it and tired the detection immune effect after 7 days);
Booster immunization (dosage 500 μ g do not add the adjuvant subcutaneous injection) after (4) three weeks;
(5) getting spleen merges.
The end is got blood examination and is surveyed antibody titer around (6) the, with physiological saline with serum dilution in 1: 10000 after, carry out ELISA and detect, be standard with the positive that develops the color.
Embodiment 3 cytogamy and screening
Put to death mouse, prepare single splenocyte suspension, in the 50ml centrifuge tube, mix 10
8Individual splenocyte and 10
7The murine myeloma cell (NS-1 cell) of individual logarithmic phase growth, and the simple substratum of adding 30ml, 800 rev/mins of room temperatures are centrifugal 8 minutes, remove supernatant liquor, centrifuge tube is put in 37 ℃ of water-baths, slowly add 0.8ml 50% (weight percent) polyoxyethylene glycol-4000, adding in 2 minutes finishes, and shakes centrifuge tube while adding, and slowly adds simple substratum then, add 4ml in 3 minutes, centrifugal 8 minutes of 800 rev/mins of room temperatures are removed supernatant liquor, add the HAT selective medium of 45ml 20% (volume percent) calf serum, be inoculated in after the piping and druming in 3 96 orifice plates, containing 5%CO
2Air in and cultivate under 37 ℃ the condition, after 7 days the nutrient solution in the culture plate is encrypted, observe after 10 days, detect the antibody titer of Hybridoma Cell Culture liquid with the ELISA method.
Embodiment 4 antibody are identified
1. the evaluation of antibodies specific: except that carrying out the detection of antibodies with immunogen (antigen), also use other antigen relevant and carry out cross matching with its antigenic component, method ELISA method, cross reacting rate all is lower than 2%, confirms that antibody is only to little peptide shown in the SEQ ID NO:1 and white-1 specificity combination of human insulin-like growth factor binding protein.
2. the Ig class of antibody and the evaluation of subclass: screen with enzyme mark or fluorescein-labeled second antibody, determine the Ig type of antibody basically; Monoclonal antibody hypotype of the present invention after measured is IgG
1
3. the evaluation of antibody relative affinity: determine McAb and corresponding antigens bonded avidity with the ELISA competition in conjunction with test, measurement result is 0.4mg/L.
Embodiment 5 antibody cloningizations
1. prepare feeder cell suspension (preparing) with before merging;
2. the counting of positive porocyte, and accent cell count is 1～5 * 10
3/ ml;
3. get 130 cells and put into 6.5ml and contain the feeder cell complete culture solution, i.e. 20 cell/ml, 100 μ l/ holes add A, B, C three rows are 2 cells in every hole.Remaining 2.9ml cell suspension is added the complete culture solution that 2.9ml contains feeder cell, and cell count is 10/ml, and 100 μ l/ holes add D, E, F three rows, are 1 cell in every hole.Remaining 2.2ml cell suspension is added the complete culture solution that 2.2ml contains feeder cell, 5/ml of cell count, and 100 μ l/ holes add G, H two rows, are 0.5 cell in every hole.
4. after cultivating 4～5 days, on inverted microscope, can see little cell clone, add complete culture solution 200 μ l/ holes.
5. the 8th～9 day the time, naked eyes visible cell clone in time carries out antibody test.
Embodiment 6 colloidal gold strips
Be embedded with the polyclonal antibody of human insulin-like growth factor binding protein white-1 respectively in the T region of nitrocellulose filter, the said monoclonal antibody that is used for catching sample human insulin-like growth factor binding protein white-1 of Radioactive colloidal gold that has been coated with mark on the Radioactive colloidal gold pad, every gold test strip bar has the 4ug monoclonal antibody.The test strip detecting end has thieving paper, inserts in the sample during reaction.
If band appears in the C district during detection, then the T district band occurs and represents that promptly sample is positive; Band do not occur and then represent feminine gender.
If band does not appear in the C district during detection, represent that then test strip lost efficacy.
Detected result is as follows:
| ? | Rupture of membranes | Rupture of membranes not |
| Detect positive | ??121 | ??3 |
| Detect negative | ??2 | ??137 |
The specificity that this Radioactive colloidal gold detects is 97.8%, and sensitivity is 98.4%.
This experiment has also adopted 0.1ug monoclonal antibody/every gold test strip bar, 50ug monoclonal antibody/every gold test strip bar to carry out related experiment respectively, and result and The above results are similar.
Embodiment 7ELISA detection kit
With the polyclonal antibody (4ug/ml) of 100ul human insulin-like growth factor binding protein white-1 with bag be cushioned liquid in every hole at 4 ℃ of bags by 24 hours, the skim-milk sealing is 24 hours then, washs, and is air-dry, sterilizes and seals standby.With the anti-human IgG or the IgM antibody of horseradish peroxidase-labeled, with the main component of TMB as colour developing liquid.
Kit package, check.
Detected result is as follows:
| ? | Rupture of membranes | Rupture of membranes not |
| Detect positive | ??120 | ??2 |
| Detect negative | ??3 | ??138 |
The specificity that this ELISA detection kit detects is 98.6%, and sensitivity is 97.5%.
In sum, the monoclonal anti physical efficiency specific detection human insulin-like growth factor binding protein white-1 of human insulin-like growth factor binding protein of the present invention white-1, Zhi Bei diagnostic reagent diagnosing premature rupture of fetal membrane specificity height is quick on the draw thus, and cost is low, be suitable for large-scale promotion application.
In this specification sheets, the present invention is described with reference to its certain embodiments.But, still can make various modifications and conversion obviously and not deviate from the spirit and scope of the present invention.Therefore, specification sheets and accompanying drawing are regarded in an illustrative, rather than a restrictive.
Sequence table
＜110〉Wuxi Bohuisi Bio-Pharmaceutical Technology Co., Ltd.
＜120〉monoclonal antibody of a kind of human insulin-like growth factor binding protein white-1, relevant host cell,
Diagnostic reagent and diagnostic kit
<160>1
<210>1
<211>23
<212>PRT
＜213〉human (Homo sapiens)
<220>
<221>domain
<222>(1)..(23)
＜223〉one section aminoacid sequence of human insulin-like growth factor binding protein white-1
<400>1
Lys?Arg?Ile?Pro?Gly?Ser?Pro?Glu?Ile?Arg?Gly?Asp?Pro?Asn?Cys
1???????????????5???????????????????10??????????????????15
Gln?Ile?Tyr?Phe?Asn?Val?Gln?Asn
20
Claims (10)
1. the monoclonal antibody of a human insulin-like growth factor binding protein white-1 is characterized in that, the antigen of described monoclonal antibody is the antigenic determinant of human insulin-like growth factor binding protein white-1.
2. the monoclonal antibody of human insulin-like growth factor binding protein according to claim 1 white-1 is characterized in that described antigenic determinant comprises the aminoacid sequence shown in the SEQ ID NO:1.
3. the monoclonal antibody of human insulin-like growth factor binding protein according to claim 2 white-1 is characterized in that described antigenic determinant is the aminoacid sequence shown in the SEQ ID NO:1.
4. a monoclonal antibody host cell is characterized in that, contains the monoclonal antibody of the arbitrary described human insulin-like growth factor binding protein of with good grounds claim 1-3 white-1.
5. monoclonal antibody host cell according to claim 4 is characterized in that, described monoclonal antibody host cell is a mouse hybridoma cell.
6. a diagnostic reagent is characterized in that, contains the monoclonal antibody of the arbitrary described human insulin-like growth factor binding protein of with good grounds claim 1-3 white-1.
7. diagnostic reagent according to claim 6 is characterized in that, the content of the monoclonal antibody of described human insulin-like growth factor binding protein white-1 is 4ug/ml.
8. a diagnostic kit is characterized in that, described diagnostic kit is a colloidal gold strip, according to the monoclonal antibody of the arbitrary described human insulin-like growth factor binding protein of claim 1-3 white-1 as colloid gold label antibody/capture antibody.
9. diagnostic reagent according to claim 8 is characterized in that, every described colloidal gold strip comprises the monoclonal antibody of the described human insulin-like growth factor binding protein of 0.1-50ug white-1
10. a diagnostic kit is characterized in that, described diagnostic kit is the ELISA test kit, according to the monoclonal antibody of the arbitrary described human insulin-like growth factor binding protein of claim 1-3 white-1 as enzyme labelled antibody/coated antibody.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910224645A CN101805406A (en) | 2009-06-26 | 2009-11-17 | Monoclonal antibody of human insulin-like growth factor binding protein-1, relative host cell, diagnostic reagent and diagnostic reagent kit |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910053915.8 | 2009-06-26 | ||
| CN200910224645A CN101805406A (en) | 2009-06-26 | 2009-11-17 | Monoclonal antibody of human insulin-like growth factor binding protein-1, relative host cell, diagnostic reagent and diagnostic reagent kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101805406A true CN101805406A (en) | 2010-08-18 |
Family
ID=42607370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910224645A Pending CN101805406A (en) | 2009-06-26 | 2009-11-17 | Monoclonal antibody of human insulin-like growth factor binding protein-1, relative host cell, diagnostic reagent and diagnostic reagent kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101805406A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102053157A (en) * | 2010-11-19 | 2011-05-11 | 广州万孚生物技术有限公司 | Test strip for fast detecting premature rupture of fetal membranes |
| CN105008925A (en) * | 2013-01-02 | 2015-10-28 | N-Dia有限责任公司 | Methods for predicting time-to-delivery in pregnant women |
| CN105242051A (en) * | 2015-09-23 | 2016-01-13 | 上海凯璟生物科技有限公司 | Up-conversion luminescence-based human insulin-like growth factor binding protein-1 (IGFBP-1) chip detection system and reagent |
| CN105504058A (en) * | 2016-02-05 | 2016-04-20 | 广州赛莱拉干细胞科技股份有限公司 | Method for preparing insulin-like growth factor binding protein 3 monoclonal antibody |
| CN110133274A (en) * | 2019-03-29 | 2019-08-16 | 南方医科大学南方医院 | IGFBPL1 is preparing the application in cardiovascular disease diagnosis reagent as marker |
-
2009
- 2009-11-17 CN CN200910224645A patent/CN101805406A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102053157A (en) * | 2010-11-19 | 2011-05-11 | 广州万孚生物技术有限公司 | Test strip for fast detecting premature rupture of fetal membranes |
| CN105008925A (en) * | 2013-01-02 | 2015-10-28 | N-Dia有限责任公司 | Methods for predicting time-to-delivery in pregnant women |
| US11353464B2 (en) | 2013-01-02 | 2022-06-07 | Qiagen Sciences, Llc | Methods for predicting time-to-delivery in pregnant women |
| CN105242051A (en) * | 2015-09-23 | 2016-01-13 | 上海凯璟生物科技有限公司 | Up-conversion luminescence-based human insulin-like growth factor binding protein-1 (IGFBP-1) chip detection system and reagent |
| CN105504058A (en) * | 2016-02-05 | 2016-04-20 | 广州赛莱拉干细胞科技股份有限公司 | Method for preparing insulin-like growth factor binding protein 3 monoclonal antibody |
| CN110133274A (en) * | 2019-03-29 | 2019-08-16 | 南方医科大学南方医院 | IGFBPL1 is preparing the application in cardiovascular disease diagnosis reagent as marker |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102445534A (en) | Combined assay kit for premature birth of pregnant woman and fetal membrane premature rupture | |
| CN101805406A (en) | Monoclonal antibody of human insulin-like growth factor binding protein-1, relative host cell, diagnostic reagent and diagnostic reagent kit | |
| CN101226196B (en) | Immunologic diagnosis kit for detecting type II dengue virus NS1 antigen | |
| Canfield et al. | Development of an assay for a biomarker of pregnancy and early fetal loss. | |
| CN103173420A (en) | Hybridoma cell capable of secreting anti-cardiac troponin I monoclonal antibodies and applications thereof | |
| CN102288753A (en) | Quadruple colloidal gold immunochromatography testing strip for rapid detection of residual tetracycline, chlortetracycline, oxytetracycline and doxycycline and preparation method of same | |
| CN112877296B (en) | Anti-phenacetin monoclonal antibody hybridoma cell strain AD and preparation method and application thereof | |
| CN1446064A (en) | Diagnostic device for distingushing between normal and ectopic pregnancy and method for preparing the same | |
| CN101551393B (en) | Immunodiagnosis kit for detecting IV-type dengue virus NS1 antigen | |
| CN101995470A (en) | Colloid gold immunochromatographic assay diagnosis method for early gestation of sows and detector | |
| CN101871943A (en) | Premature rupture of membrane fast examination tool using ICAM-1 as examination index and examination kit | |
| CN101130765A (en) | Reagent kit for detecting syncytial virus of respiratory passage | |
| CN111334478A (en) | Hybridoma cell strain for detecting canine distemper virus and canine parvovirus and double detection test paper card thereof | |
| CN109112114A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN109112113A (en) | Monoclonal antibody, hybridoma cell strain, kit and its application of anti-human igg | |
| CN109082413A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN101726593B (en) | Immunologic diagnosis kit for detecting dengue virus NS1 antigen and application thereof | |
| CN101216493A (en) | Test paper for diagnosing premature rupture of fetal membrane and reagent kit | |
| CN100554965C (en) | Toxoplasmosis IgM antigen testing reagent and application | |
| CN101738474A (en) | Combined test reagent card for cytomegalovirus and rubella virus | |
| CN109280644A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN102898517B (en) | Anti-West Nile virus non-structural protein 1 antibodies and application thereof | |
| CN102659929B (en) | Transient receptor potential channel-6 (TRPC6) antigen polypeptide and anti-TRPC6 monoclonal antibody | |
| CN105838680B (en) | One plant of anti-estriol monoclonal antibody specific hybridoma cell strain NaN-2 and its application | |
| CN212808318U (en) | Test strip for detecting fetal fibronectin and human insulin-like growth factor binding protein-1 and device comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wei Yanyu Inventor after: Liu Li Inventor after: Lei Zhen Inventor after: Zhang Lixin Inventor after: Li Yali Inventor after: Chen Daozhen Inventor after: Wu Jinbao Inventor before: Wei Yanyu Inventor before: Liu Li Inventor before: Lei Zhen Inventor before: Zhang Lixin Inventor before: Li Yali |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WEI YANYU LIU LI LEI ZHEN ZHANG LIXIN LI YALI TO: WEI YANYU LIU LI LEI ZHEN ZHANG LIXIN LI YALI CHEN DAOZHEN WU JINBAO |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20100818 |